Chris Wagner: The role of Eden Radioisotopes in the future of nuclear medicine

August 1, 2025, 3:03PMNuclear News
Chris Wagner, chief executive officer of Eden Radioisotopes. Inset: Fission Mo-99 process. (Images: Eden)

Chris Wagner has more than 40 years of experience in nuclear medicine, beginning as a clinical practitioner before moving into leadership roles at companies like Mallinckrodt (now Curium) and Nordion. His knowledge of both the clinical and the manufacturing sides of nuclear medicine laid the groundwork for helping to found Eden Radioisotopes, a start-up venture that intends to make diagnostic and therapeutic raw material medical isotopes like molybdenum-99 and lutetium-177.

To continue reading, log in or create a free account!